RADX (Radiopharm Theranostics) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RADX Radiopharm Theranostics Ltd RADX
33 GF Score
Price $2.08
GF Value $2.34
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Radiopharm Theranostics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

RADX
33GF Score
Radiopharm Theranostics Ltd RADX
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Radiopharm Theranostics (RADX) Overvalued in 2026?

Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued. The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34. GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.

Key valuation signals for RADX:

  • Dividend-Payout-to-FFO:
  • GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radiopharm Theranostics Business Description

Other Exchanges RAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score

Get the complete analysis for RADX

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$2.34
GF Value